Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;10(12):4368-4379.
doi: 10.21037/tlcr-21-682.

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer

Zhen Wang  1   2 , Lingyun Wei  3 , Jing Li  2 , Han Zhou  2 , Si Li  4 , Dongsheng Chen  4 , Yangyang Yu  4 , Lele Zhao  4 , Xixu Zhu #  2 , Yong Song #  1   5
Affiliations

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer

Zhen Wang et al. Transl Lung Cancer Res. 2021 Dec.

Erratum in

Abstract

Background: Immunotherapy has brought substantial benefit for patients with advanced non-small cell lung cancer (NSCLC); however, resistance may occur, of which oligoprogression is most common. There are no standard strategies to overcome acquired resistance, thus exploring potential effective approaches is critical. Our study evaluated the clinical outcome of combing stereotactic body radiotherapy (SBRT) with checkpoint inhibitors (CPIs) in oligoprogressive NSCLC.

Methods: We retrospectively reviewed patients with advanced NSCLC who received SBRT for oligoprogressive lesions after acquired resistance to CPIs in our hospital between January 2015 and January 2021. Acquired resistance was defined as initial complete/partial response (CR/PR) followed by progression/death. Oligo patterns of acquired resistance were defined as progression in ≤2 sites of disease. We evaluated the local control rate (LR), progression-free survival (PFS-PO), overall survival (OS-PO), and safety of combing SBRT after oligoprogression.

Results: Among 177 patients reviewed, 24 patients were included. Fifteen (62.5%) were diagnosed with adenocarcinoma, and 20 (83.3%) were with stage IV. Before oligoprogression, immunotherapy was used as first-line treatment in 16 (66.7%) patients, and 4 (16.7%) received monotherapy. After combing SBRT with CPIs, the median PFS-PO and OS-PO were 11 months (95% CI: 8-NA) and 34 months (95% CI: 19-NA). The median LC of 34 oligoprogressed lesions was 43 months (95% CI: 7.7-78.3). The 1- and 2-year LC rates were 100% and 81.8%, respectively. Patients with adenocarcinoma, lung immune prognostic index (LIPI) (≥1), and positive PD-L1 tended to achieve favorable survival benefits.

Conclusions: We observed considerable benefit of local control and survival by combing SBRT in patients with oligoprogression after required resistance to CPIs in NSCLC. The adverse events are well managed. Our results suggest that combing SBRT with CPIs could be a potential strategy to overcome acquired resistance.

Keywords: Non-small cell lung cancer (NSCLC); checkpoint Inhibitor (CPI); oligoprogression; stereotactic body radiotherapy (SBRT); survival.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/tlcr-21-682). Yong Song serves as an Editor-in-Chief of Translational Lung Cancer Research. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of patient selection. SBRT, stereotactic body radiotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressed disease.
Figure 2
Figure 2
Kaplan-Meier curves of progression-free survival (PFS) (A), progression-free survival post oligoprogression (PFS-PO) (B), overall survival (OS) (C) and overall survival post oligoprogression (OS-PO) (D).
Figure 3
Figure 3
Swimming plot visualizing the response details for immunotherapy and combing SBRT to checkpoint inhibitors (CPIs) after oligoprogression in 24 patients.
Figure 4
Figure 4
Kaplan-Meier curve of local control (LC) in 34 oligoprogressed lesions.
See this image and copyright information in PMC

References

    1. Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of lung cancer. Contemp Oncol (Pozn) 2021;25:45-52. 10.5114/wo.2021.103829 - DOI - PMC - PubMed
    1. Sui H, Ma N, Wang Y, et al. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. J Immunol Res 2018;2018:6984948. 10.1155/2018/6984948 - DOI - PMC - PubMed
    1. Schoenfeld AJ, Rizvi H, Memon D, et al. Acquired resistance to PD-1 blockade in NSCLC. J Clin Oncol 2020;38:9621. 10.1200/JCO.2020.38.15_suppl.9621 - DOI
    1. Rheinheimer S, Heussel CP, Mayer P, et al. Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors. Cancers (Basel) 2020;12:1046. 10.3390/cancers12041046 - DOI - PMC - PubMed
    1. Gettinger SN, Wurtz A, Goldberg SB, et al. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2018;13:831-9. 10.1016/j.jtho.2018.03.008 - DOI - PMC - PubMed